Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
Redig AJ, Munshi HG. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park). 2010 Aug; 24(9):839-44.